| pubmed-article:20145548 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20145548 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:20145548 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:20145548 | lifeskim:mentions | umls-concept:C0011306 | lld:lifeskim |
| pubmed-article:20145548 | lifeskim:mentions | umls-concept:C0332466 | lld:lifeskim |
| pubmed-article:20145548 | lifeskim:mentions | umls-concept:C1332709 | lld:lifeskim |
| pubmed-article:20145548 | lifeskim:mentions | umls-concept:C0079411 | lld:lifeskim |
| pubmed-article:20145548 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20145548 | pubmed:dateCreated | 2010-2-24 | lld:pubmed |
| pubmed-article:20145548 | pubmed:abstractText | Adoptive immunotherapy with tumor-specific T cells represents a promising treatment strategy for patients with malignancy. However, the efficacy of T-cell therapy has been limited by the ability to expand tumor-reactive cells with an activated phenotype that effectively target malignant cells. We have developed an anticancer vaccine in which patient-derived tumor cells are fused with autologous dendritic cells (DCs), such that a wide array of tumor antigens are presented in the context of DC-mediated costimulation. In this study, we demonstrate that DC/tumor fusions induce T cells that react with tumor and are dramatically expanded by subsequent ligation of the CD3/CD28 costimulatory complex. These T cells exhibit a predominantly activated phenotype as manifested by an increase in the percentage of cells expressing CD69 and interferon gamma. In addition, the T cells upregulate granzyme B expression and are highly effective in lysing autologous tumor targets. Targeting of tumor-specific antigen was demonstrated by the expansion of T cells with specificity for the MUC1 tetramer. Stimulation with anti-CD3/CD28 followed by DC/tumor fusions or either agent alone failed to result in a similar expansion of tumor-reactive T cells. Consistent with these findings, spectratyping analysis demonstrates selective expansion of T-cell clones as manifested by considerable skewing of the Vbeta repertoire following sequential stimulation with DC/tumor fusions and anti-CD3/CD28. Gene expression analysis was notable for the upregulation of inflammatory pathways. These findings indicate that stimulation with DC/tumor fusions provides a unique platform for subsequent expansion with anti-CD3/CD28 in adoptive T-cell therapy of cancer. | lld:pubmed |
| pubmed-article:20145548 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20145548 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20145548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20145548 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20145548 | pubmed:issn | 1537-4513 | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:StoneRichardR | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:NeubergDonnaD | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:TzachanisDimi... | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:KufeDonaldD | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:AviganDavidD | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:JoyceRobinR | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:Konstantinopo... | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:VasirBaldevB | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:SpentzosDimit... | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:WuZekuiZ | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:RosenblattJac... | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:Ghebremichael... | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:StevensonKris... | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:BoussiotisVas... | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:ZarwanCorrine... | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:MillsHeidiH | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:FriedmanTheaT | lld:pubmed |
| pubmed-article:20145548 | pubmed:author | pubmed-author:LevineJames... | lld:pubmed |
| pubmed-article:20145548 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20145548 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:20145548 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20145548 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20145548 | pubmed:pagination | 155-66 | lld:pubmed |
| pubmed-article:20145548 | pubmed:dateRevised | 2010-12-3 | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:meshHeading | pubmed-meshheading:20145548... | lld:pubmed |
| pubmed-article:20145548 | pubmed:articleTitle | Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. | lld:pubmed |
| pubmed-article:20145548 | pubmed:affiliation | Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. jrosenb1@bidmc.harvard.edu | lld:pubmed |
| pubmed-article:20145548 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20145548 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20145548 | lld:pubmed |
